EN DE
Watch Sophia Genetics SA for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Sophia Genetics SA (SOPH) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Sophia Genetics SA stock $5.60, price $7.86, that is 28.8% below the price, quality 30 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Home Switzerland · ISIN CH1125843347

SG Sophia Genetics SA logo Thin data Nov 11, 2026

Sophia Genetics SA

SOPH · US
Expensive, weak quality

Our calculation puts a fair price 29% below what the stock costs today.

Revenue last quarter +25% vs. a year ago.
Expensive Growth (revenue 5y +22.2 %/yr in USD)
Moderate debt
Insiders bought $377,388 (6M) · sold $4.2M
Fair value $5.60 · Overvalued
Quality 30/100
Loss-making · -89.2% net margin (TTM)
Negative free cash flow
Trails peers (1/10)
Narrow moat 15/100
Thin data
Estimate
Watch Sophia Genetics SA for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$19.77 $1.71 Fair Value $5.60 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range $1.71 – $19.77 · fair‑value band $4.20 – $7.00 · the $7.86 price screens above the $5.60 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.

Follow Sophia Genetics in your weekly email

Every Wednesday you see whether Sophia Genetics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities.

Show moreShow less

Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.

The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom. The company was incorporated in 2011 and is based in Rolle, Switzerland.

Stock analysis

Sophia Genetics SA (SOPH) currently trades at $7.86, while our estimate is $5.60, 29% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $4.20 (bear) to $7.00 (bull), the price of $7.86 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Sophia Genetics SA reported revenue of $77.3M in FY2025 versus $40.5M in FY2021, a compound +17.6%/yr. Reported net income was −$79.0M in FY2025.

Key figures

Market cap $642M Small · P/S ratio 7.05 · EPS (TTM) $−1.09 · Net margin −89.2% · Return on equity −126% · Return on assets (EBIT) −36.2% (5-year average) · Operating margin −73.5% · Revenue (TTM) $91.0M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 15 out of 100 (medium confidence).

What moves the price

The share trades about 12% below its 52-week high and 102% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −35% fair-value upside, at −29%, SOPH screens cheaper than that median.

Fair Value

Bear $4.20 Fair Value $5.60 Bull $7.00
Price $7.86 · Downside -28.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 16
How much profit the company makes from its sales and capital
Quality Growth 31
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 45
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 27
How calm the share price moves, does not count
Price momentum 85
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 90
Distance to the 52-week high, does not count
New shares 18
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 2 officers or directors bought shares worth $377,388, most recently on Nov 6, 2026. Over the same period, 10 people sold shares worth $4.2M. Buying cluster

  • BuyRoss MukenChief Executive Officer, Director20,000 shares at $6.86$137,188Nov 6, 2026
  • BuyGeorge CardozaChief Financial Officer2× since Jun 5, 2026: 40,000 shares, avg. $6.01$240,200Nov 6, 2026
  • SaleZhenyu XuChief Scientific Officer19× since Mar 19, 2026: 119,167 shares, avg. $6.83$814,029Oct 13, 202610b5-1 plan
  • SaleJurgi CamblongExecutive Chairman, Director20× since Mar 19, 2026: 451,386 shares, avg. $6.05$2.7MOct 12, 202610b5-1 plan
  • SalePhilippe MenuChief Medical Officer20× since Mar 19, 2026: 91,167 shares, avg. $5.91$538,879Oct 12, 202610b5-1 plan
  • SaleRoss MukenChief Executive Officer, Director11× since Mar 19, 2026: 43,913 shares, avg. $5.69$249,741Oct 5, 202610b5-1 plan
  • SaleGeorge CardozaChief Financial Officer7× since Mar 19, 2026: 11,842 shares, avg. $5.61$66,440Oct 5, 202610b5-1 plan
  • SaleKevin PuylaertChief Sales Officer7× since Mar 19, 2026: 1,158 shares, avg. $5.48$6,345Oct 5, 2026
  • SaleAbhimanyu VermaChief Technology Officer7× since Apr 6, 2026: 41,062 shares, avg. $6.90$283,152Oct 5, 202610b5-1 plan
  • SaleManuela ValenteChief People Officer8× since Mar 19, 2026: 28,418 shares, avg. $6.46$183,562Oct 5, 202610b5-1 plan

Plus 2 more entries from the last 12 months.

Plus 10 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+18.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.2%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−131.6% (2020) → −91.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

SOPH screens overvalued: fair value 29% below the price. Compare with Veeva Systems Inc →

Compare Sophia Genetics SA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 141 stocks

Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −28.8% · Below median
Profitability
Return on assets −48.3% · Bottom 25%
Net margin (12 months) −89.2% · Bottom 25%
Operating margin (12 months) −73.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 24.7% · Top 25%
Balance sheet
Debt / equity 1.01× · Highest 25%

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/B 13.61× · Priciest 25%
P/S (12 months) 7.05× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 13
FUTURE (revenue growth)100 · sector 45
PAST (return on equity)0 · sector 0
HEALTH (low debt)49 · sector 98
DIVIDEND (yield)0 · sector 46

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Doximity, Inc DOCS $32.42 $36.16 +12% vs SOPH
Veeva Systems Inc VEEV $305.55 $337.04 +10% vs SOPH
HealthEquity, Inc HQY $103.54 $112.32 +8% vs SOPH
Waystar Holding WAY $29.30 $29.10 −1% vs SOPH
Tempus AI, Inc TEM $80.54 $52.58 −35% vs SOPH
HeartFlow, Inc HTFL $55.80 $34.82 −38% vs SOPH
Hinge Health, Inc HNGE $123.23 $51.25 −58% vs SOPH
Pro Medicus Limited PME A$207.31 A$85.12 −59% vs SOPH
BrightSpring Health Services, Inc BTSG $72.49 $25.72 −65% vs SOPH
XtalPi Holdings 2228 HK$6.37 HK$1.53 −76% vs SOPH

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sophia Genetics SA: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Sophia Genetics SA Fair Value". https://www.fairvalue-calculator.com/stock/SOPH

Frequently asked questions

Is Sophia Genetics SA (SOPH) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is $5.60 versus a price of $7.86, about 29% lower (overvalued).
What is the fair value of SOPH?
Our estimate for Sophia Genetics SA is $5.60 (as of Nov 11, 2026), built from audited fundamentals. The current price: $7.86.
What is the quality score of SOPH?
Sophia Genetics SA has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sophia Genetics SA (SOPH)?
Our calculated price target is the estimate of $5.60 (as of Nov 11, 2026). Cautious scenario $4.20, optimistic scenario $7.00. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Sophia Genetics SA stock forecast for 2026?
Our estimate puts fair value at $5.60, about 29% lower versus a price of $7.86 (overvalued). Cautious scenario $4.20, optimistic scenario $7.00. The calculation is refreshed regularly with new filings.
What is the revenue of Sophia Genetics SA (SOPH)?
Sophia Genetics SA reported trailing-twelve-month revenue of about $91.0M (latest available figure, as of Nov 11, 2026).
What is the intrinsic value of Sophia Genetics SA (SOPH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sophia Genetics SA it is $5.60 per share (as of Nov 11, 2026), against a price of $7.86.
Is Sophia Genetics SA stock overvalued or undervalued in 2026?
As of Nov 11, 2026, SOPH trades above its calculated fair value: price $7.86, fair value $5.60, a gap of about −29% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SOPH?
No. The price is what the market pays today ($7.86); the fair value is what the company's own numbers justify ($5.60). For Sophia Genetics SA the two are $2.26 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sophia Genetics SA worth?
The market values Sophia Genetics SA at about $642M (market capitalisation, as of Nov 11, 2026). Per share that is $7.86; our models calculate a fair value of $5.60 per share.
What do the bullish and bearish scenarios say about SOPH?
Our models span a range for Sophia Genetics SA: cautious scenario $4.20, base $5.60, optimistic $7.00 per share (as of Nov 11, 2026, price $7.86). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sophia Genetics SA (SOPH)?
Balance-sheet figures for Sophia Genetics SA (as of Nov 11, 2026): return on equity −125.7%, debt of 1.01 per unit of equity. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is SOPH from its 52-week high?
Sophia Genetics SA trades at $7.86, about 12% below its 52-week high of $8.92 and 102% above the low of $3.89 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $5.60 is for.
Which stocks are comparable to Sophia Genetics SA?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Tempus AI, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sophia Genetics SA stock attractive at the current price?
The data as of Nov 11, 2026: price $7.86, calculated fair value $5.60 (−29%), Quality Score 30/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Sophia Genetics SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sophia Genetics SA (SOPH)?
The closing price on Nov 10, 2026 was $7.86. Our estimate is $5.60, about 29% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sophia Genetics SA right now?
The price sits above even our optimistic bull case ($7.00). The favourable scenario is already priced in. Weak quality (30/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Sophia Genetics SA

How large is the market capitalisation of Sophia Genetics SA (SOPH)?
The market capitalisation of Sophia Genetics SA is $642M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sophia Genetics SA (SOPH)?
The price-to-sales ratio of Sophia Genetics SA is 7.05 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sophia Genetics SA (SOPH)?
Earnings per share at Sophia Genetics SA are $−1.09. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sophia Genetics SA (SOPH)?
The net margin of Sophia Genetics SA is −89.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sophia Genetics SA (SOPH)?
The return on equity (ROE) of Sophia Genetics SA is −126% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sophia Genetics SA (SOPH)?
On an EBIT basis the return on assets of Sophia Genetics SA is −36.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sophia Genetics SA (SOPH)?
The operating margin of Sophia Genetics SA is −73.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sophia Genetics SA (SOPH)?
Revenue at Sophia Genetics SA is growing +24.7% versus a year earlier (3y avg +17.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Sophia Genetics SA (SOPH) generate?
The free cash flow of Sophia Genetics SA is −$38.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Sophia Genetics SA (SOPH) hold?
Sophia Genetics SA holds more cash than debt, $7.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Sophia Genetics SA in the live analysis

One click puts Sophia Genetics SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.